As per the research report, the size of the Middle East and Africa Transfection Reagents and Equipment market size is valued at USD 33.06 million in 2019. It is expected to grow at a CAGR of 5.6 % to reach USD 43.45 million by 2024 during the forecast period 2019-2024. It has the lowest market share of 4%.
The process of inserting genetic material, such as DNA and double-stranded RNA, into mammalian cells is called transfection. Transfection reagents are the substances containing the genetic material whereas the equipment is used as a delivery mechanism.
Many technological advancements happening in the transfection reagents and equipment market over the years has to a certain extent addressed the requirements of researchers and biotechnology & biopharmaceutical companies. Transfection instruments with higher efficiency are the result of these advancements. In addition, efficient quantitative and qualitative transfection in a wide variety of cells, including the hard-to-transfect cells is also the result of this.
Technological advancements in transfections, alliances worldwide between the pioneering research institutes to trigger drug discovery, augmented research and development spending along with research activities by pharmaceutical and biotechnology companies, rise in demand for synthetic genes and increasing number of cases of cancer are driving the growth of this market.
Selective effectiveness of transfection reagents, homebrew reagents by researchers conjoined with hefty costs of transfection reagents are the primary factors expected to slow down the growth of this market.
This research report segmented and sub-segmented into the following categories:
In 2016, the academic & research institutes category is likely to command the largest market share. Although, the pharmaceutical & biotechnologies category is estimated to grow at the highest CAGR during the aforementioned forecast period. It is the last in terms of market share.
The leading companies leading in the MEA Transfection Reagents and Equipment Market profiled in the report are Thermo Fisher Scientific Inc. (U.S.), Promega Corporation (U.S.), Hoffmann-La Roche Ltd. (Switzerland), and QIAGEN N.V. (Netherlands). These companies hold a leading position in the transfection reagent and equipment market because of their well-established presence in the fields of genomics, spanning fifty countries, heavy R&D investments, and strong sales as well as distribution force. Other players in the market include Polyplus-transfection SA (France), Bio-Rad Laboratories (U.S.), Lonza Group (Switzerland), Sigma-Aldrich Corporation (U.S.), Mirus Bio LLC (U.S.), and MaxCyte Inc. (U.S.).,
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Reagents
5.1.2 Instruments
5.1.3 Y-o-Y Growth Analysis, By Product
5.1.4 Market Attractiveness Analysis, By Product
5.1.5 Market Share Analysis, By Product
5.2 Method
5.2.1 Biochemical
5.2.2 Calcium Phosphate
5.2.2.1 Lipofection
5.2.2.1.1 Advantages
5.2.2.1.2 Disadvantages
5.2.2.2 Calcium Phosphate
5.2.2.2.1 Advantages
5.2.2.2.2 Disadvantages
5.2.2.3 DEAE-dextran
5.2.2.3.1 Advantages
5.2.2.3.2 Disadvantages
5.2.2.4 Dendrimers
5.2.2.4.1 Advantages
5.2.2.5.1 Disadvantages
5.2.3 Physical
5.2.3.1 Electroporation
5.2.3.1.1 Advantages
5.2.3.1.2 Disadvantages
5.2.3.2 Nucleofection
5.2.3.2.1 Advantages
5.2.3.2.2 Disadvantages
5.2.3.3.Others
5.2.3.3.1 Sonoporation
5.2.3.3.2 Genegun
5.2.3.3.2.1 Advantages
5.2.3.3.2.2 Disadvantages
5.2.3.3.3 Magnetofection
5.2.3.3.3.1 Advantages
5.2.3.3.3.2 Disadvantages
5.2.3.3.4 Optoinjection
5.2.3.3.4.1 Advantages
5.2.3.3.4.2 Disadvantages
5.2.4 Viral
5.2.4.1 Adenoviruses
5.2.4.2 Retroviruses
5.2.4.3 Adenoassociated Viruses (AAV)
5.2.5 Y-o-Y Growth Analysis, By Method
5.2.6 Market Attractiveness Analysis, By Method
5.2.7 Market Share Analysis, By Method
5.3 Application
5.3.1 Biomedical Research
5.3.1.1 Gene Expression Studies
5.3.1.2 Cancer Research
5.3.1.3 Transgenic Model
5.3.2 Protein Production
5.3.3 Therapeutic Delivery
5.3.4 Y-o-Y Growth Analysis, By Application
5.3.5 Market Attractiveness Analysis, By Application
5.3.6 Market Share Analysis, By Application
5.4 End User
5.4.1 Academic & Research Institutes
5.4.2 Pharmaceutical & Biotechnology Companies
5.4.3 Y-o-Y Growth Analysis, By End User
5.4.4 Market Attractiveness Analysis, By End User
5.4.5 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Method
6.1.3.4 By Application
6.1.3.5 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Method
6.1.4.4 By Application
6.1.4.5 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Method
6.1.5.4 By Application
6.1.5.5 By End User
6.2 Middle-East
6.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Thermo Fisher Scientific Inc. (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Promega Corporation (U.S.)
8.3 Hoffmann-La Roche Ltd. (Switzerland)
8.4 QIAGEN N.V. (Netherlands)
8.5 Polyplus-transfection SA (France)
8.6 Bio-Rad Laboratories (U.S.)
8.7 Lonza Group (Switzerland)
8.8 Sigma-Aldrich Corporation (U.S.)
8.9 Mirus Bio LLC (U.S.)
8.10 MaxCyte Inc. (U.S.)
9.Competitive Landscape
9.1 Market share analysis &
Related Reports
